Slioui, A, Tammam, G, Vanoli, F, Della Marina, A, Vohanka, S, Gilhus, NE, Moroni, I, Leite, MI, Piehl, F, Antozzi, C, Pini, J, Stascheit, F, Attarian, S, Santos, E, Verschuuren, J, Canonge, L, Garcia, J, Perriard, C, Cortés-Vicente, E, Mantegazza, R, Meisel, A, Sacconi, S. Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data. Orphanet Journal of Rare Diseases. 2025; 20(1)DOI:10.1186/s13023-024-03520-3. PMID:40069719. IF:3.500(Q2/4D).

Caballero-avila, M, Martin-Aguilar, L, Pascual-Goni, E, Michael, MR, Koel-Simmelink, MJA, Hoeftberger, R, Wanschitz, J, Alonso-Jimenez, A, Armangue, T, Baars, AE, Carbayo, A, Castek, B, Collet-Vidiella, R, De Winter, J, del Real, MA, Delmont, E, Diamanti, L, Doneddu, PE, Hiew, FL, Gallardo, E, Gonzalez, A, Grinzinger, S, Horga, A, Iglseder, S, Jacobs, BC, Jauregui, A, Killestein, J, Pozza, EL, Martinez-Martinez, L, Nobile-Orazio, E, Ortiz, N, Perez-Perez, H, Poppert, KN, Ripellino, P, Roche, JC, de Rivera, FJR, Rostasy, K, Sparasci, D, Tejada-Illa, C, Teunissen, CCE, Vegezzi, E, Xucla-Ferrarons, T, Zach, F, Wieske, L, Eftimov, F, Lleixa, C, Querol, L. Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy. ANNALS OF NEUROLOGY. 2025; 97(3)DOI:10.1002/ana.27142. PMID:39601182. IF:7.700(Q1/1D).

Querol, L, Dalakas, MC. The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology. Neurology-Neuroimmunology & Neuroinflammation. 2025; 12(1)DOI:10.1212/NXI.0000000000200365. PMID:39671536. IF:7.500(Q1/1D).

Reyes-Leiva, D, Carbayo, A, Vesperinas-Castro, A, Rojas-Garcia, R, Querol, L, Turon-Sans, J, Pla-Junca, F, Olivé, M, Gallardo, E, Pujades-Rodriguez, M, Cortés-Vicente, E. Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(1)DOI:10.1111/ene.16463. PMID:39624955. IF:3.900(Q1/3D).

Cortes-Vicente, E, Guerrero-Sola, A, Caballero-Martinez, F, Campos-Lucas, FJ, Gómez-Salgado, J, Monge-Martin, D, Alvarez-Velasco, R. Practitioner's perception of myasthenia gravis management recommendations in clinical practice: a cross-sectional survey study. Therapeutic Advances in Chronic Disease. 2025; 16DOI:10.1177/20406223251368063. PMID:40949050. IF:2.800(Q2/5D).

Leonhard, SE, Papri, N, Querol, L, Rinaldi, S, Shahrizaila, N, Jacobs, BC. Guillain-Barre syndrome. Nature Reviews Disease Primers. 2024; 10(1)DOI:10.1038/s41572-024-00580-4. PMID:39702645. IF:60.600(Q1/1D).

Seminario, FD, Aventin, BP, Eiros, R, Freire, JL, Sevilla, T, Carbayo, A, Llongueras, P, Garcia-Alvarez, A, Ripoll-Vera, T, Macias, R, Vilches, S, Ruiz-Bustillo, S, Achaga, XA, Ordas, JG, Gonzalez-Costello, J. Hereditary transthyretin amyloidosis caused by Val142Ile variant in Spain: phenotypic characteristics, geographic distribution and population frequency. EUROPEAN HEART JOURNAL. 2024; 45DOI:10.1093/eurheartj/ehae666.2073. PMID:. IF:35.600(Q1/1D).

Gawinska, KA, García, MF, Osorio, AN, Paradas, C, Sotoca, J, Povedano, M, Moreno, A, Henao, M, Gil, C, Rojas, R, Caravaca, MG, Grimalt, M, Torron, RF, Jericó, I, Campos, OG, de Laguna, LTB, Hervás, D, Tizzano, E, Costa, JV. Natural history of spinal muscular atrophy patients with 3 and 4 copies of SMN2 gene - data from the national Spanish registry (CUIDAME). NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.461. PMID:. IF:2.800(Q2/5D).

Collins, C, Gokul-Nath, R, Katsikis, P, Fernández-Simón, E, Villalobos, E, Monceau, A, Reza, M, Mehra, P, Laidler, Z, Clark, J, Rojas-García, R, Tasca, G, Marini-Bettolo, C, Diaz-Manera, J. SnRNAseq analysis of muscle samples of patients with SMA reveals novel pathogenic pathways and open avenues for new therapeutic strategies. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.611. PMID:. IF:2.800(Q2/5D).

Hilsden, H, James, M, Dressman, HG, Rufibach, L, Day, J, Mendell, J, Torron, RF, Harms, M, Pestronk, A, Vissing, J, Desai, U, Yoshimura, M, Shin, J, Mozaffar, T, Stojkovic, T, Pegoraro, E, Rivas, JB, Olive, M, Paradas, C, Straub, V. The International Clinical Outcome Study for Dysferlinopathy II: validation of motor outcome measures in a new patient cohort. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.276. PMID:. IF:2.800(Q2/5D).

Marín, RM, Leiva, DR, Osorio, AN, Muelas, N, Domínguez, C, Marcos, IR, Paradas, C, Olivé, M, Matas, A, Caravaca, MG, Romero, MB, Mendoza, M, de León, J, Gutiérrez, A, Rabasa, M, Segovia, S, Manera, JD. Spanish Pompe Registry: overview based on the 130 patients included. NEUROMUSCULAR DISORDERS. 2024; 43DOI:10.1016/j.nmd.2024.07.732. PMID:. IF:2.800(Q2/5D).

Segarra-Casas, A, Domínguez-González, C, Natera-De-Benito, D, Ortez, C, Nascimiento, A, Hernández-Laín, A, Kapetanovic, S, Rodríguez, M, González-Mera, L, Nedkova, V, Fernández-Torrón, R, López-de Munain, A, Jimenez-Mallebrera, C, Rodríguez-Santiago, B, Gallardo, E, Olivé, M, Gallano, P, González-Quereda, L. RNA sequencing as a diagnostic tool in a cohort of 54 undiagnosed patients with neuromuscular diseases. NEUROMUSCULAR DISORDERS. 2024; 43DOI:. PMID:. IF:2.800(Q2/5D).

Monreal, E, Medrano, N, Rodriguez, ABC, Dominguez, JMG, Querol, L, Lallana, JM, Landete, L, Garcia, ME, Morales, EA, Meca, V, Yelamos, SM, Maurino, J, Gómez, R, Guimerans, LMV. Attitudes towards serum neurofilament light chain testing: The role of evidence-based innovation among neurologists. Multiple Sclerosis Journal. 2024; 30(3)DOI:. PMID:. IF:5.000(Q1/2D).

Rodriguez, ABC, Medrano, N, Guimerans, LMV, Querol, L, Lallana, JM, Yelamos, SM, Landete, L, Dominguez, JMG, Gómez, R, Meca, V, Morales, EA, Maurino, J, Garcia, ME, Mora, P, Monreal, E, Saposnik, G. Empathy in multiple sclerosis care: Differences between female and male neurologists. Multiple Sclerosis Journal. 2024; 30(3)DOI:. PMID:. IF:5.000(Q1/2D).

Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F, CIDP01 Study Investigators. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024; 95(9)DOI:10.1136/jnnp-2023-333112. PMID:38729747. IF:(Q/D).

Andújar-Sánchez, F, Cantó-Santos, J, Fernández-Garibay, X, Valls-Roca, L, Tobías, E, Guitart-Mampel, M, García-García, FJ, Laudo, B, Vilaseca-Capel, A, Padrosa, J, Moreno-Lozano, PJ, Grau-Junyent, JM, Matas, A, Gallardo, E, Fernández-Costa, J, Ramón-Azcón, J, Milisenda, JC, Garrabou, G. Novel patient-derived 2D and 3D muscle models in inclusion body myositis. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).

Asl, AM, Mehdizadeh, M, Kulisevsky, J, Sabet, A, Sharabiani, PTA, Mehdizadeh, H, Ashayeri, H, Taghizadeh, G. Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease. DISABILITY AND REHABILITATION. 2022; 44(10)DOI:10.1080/09638288.2020.1813337. PMID:32924645. IF:2.200(Q2/4D).

Aracil-Bolanos, I, Sampedro, F, Marin-Lahoz, J, Horta-Barba, A, Martinez-Horta, S, Gonzalez-de-Echavarri, JM, Perez-Perez, J, Bejr-Kasem, H, Pascual-Sedano, B, Boti, M, Campolongo, A, Izquierdo, C, Gironell, A, Gomez-Anson, B, Kulisevsky, J, Pagonabarraga, J. Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment. Brain Imaging and Behavior. 2022; 16(2)DOI:10.1007/s11682-021-00543-3. PMID:34553331. IF:3.200(Q2/5D).

Aracil-Bolanos, I, Martinez-Horta, S, Gonzalez-de-Echavarri, JM, Sampedro, F, Perez-Perez, J, Horta, A, Campolongo, A, Izquierdo, C, Gomez-Anson, B, Pagonabarraga, J, Kulisevsky, J. Structure and Dynamics of Large-Scale Cognitive Networks in Huntington's Disease. MOVEMENT DISORDERS. 2022; 37(2)DOI:10.1002/mds.28839. PMID:34752656. IF:8.600(Q1/1D).

Aretouli, E, Chondrogiorgi, M, Dede, O, Koutsonida, M, Lafi, C, Konstantinopoulou, E, Kulisevsky, J, Kosmidis, MH, Konitsiotis, S. The Parkinson's Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2022; 35(5)DOI:10.1177/08919887211049110. PMID:34663111. IF:2.600(Q3/7D).